Sun Pharma presents data from Phase 1 studies of GL0034
GL0034 is a novel, investigational glucagon-like peptide 1 receptor agonist (GLP-1RA) being studied for the treatment of type 2 diabetes and obesity
GL0034 is a novel, investigational glucagon-like peptide 1 receptor agonist (GLP-1RA) being studied for the treatment of type 2 diabetes and obesity
The product will be produced at the Eugia Pharma Specialities, Unit-I, Medchal, Malkajgiri District, Telangana, India
The company will submit its comprehensive response on these observations to the USFDA
The company expects to capture a 10 per cent share in Spain’s $6.34 million meropenem market and consolidate its position in other European countries
Augnito’s AI comprehends all English accents with 99% accuracy
Antimicrobial Resistance (AMR) poses a significant threat to global healthcare systems and patient safety
Effective disaster response and management is a collaborative work
This partnership will revolutionize Pharmarack's digital infrastructure with Snowflake's single, integrated platform to facilitate advanced analytic
Subscribe To Our Newsletter & Stay Updated